Phase 2 Study of Anlotinib in Advanced Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 23 May 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 12 Jun 2018 Status changed from active, no longer recruiting to completed based on the results published in the Clinical Cancer Research.
- 12 Jun 2018 Results published in the Clinical Cancer Research.
- 10 May 2018 According to the Sino Biopharmaceutical media release, data from this trial was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.